Previous 10 | Next 10 |
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is one of today's top gainers. The company's shares are currently up 25.79% on the day to $18.78. IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeuti...
2023-04-24 10:08:54 ET Gainers: IN8bio ( INAB ) +121% . IDEAYA Biosciences ( IDYA ) +27% . ZyVersa Therapeutics ( ZVSA ) +26% . Koninklijke Philips ( PHG ) +15% . Kiora Pharmaceuticals ( KPRX ) +9% . Losers: Scilex H...
2023-04-24 09:13:31 ET Getty Images Holdings ( GETY ) +59% proposes to acquire Getty Images for $10 per share. IN8bio ( INAB ) +38% Presents Positive, New INB-100 Data Showing Long-term Complete Remissions and Elevated Gamma-Delta T Cells in 100% of Evaluable Tre...
2023-04-23 12:00:00 ET Biotech deal-making is on a roll, with more than $12B worth of transactions announced over the past week alone, and, according to industry observers, the trend is expected to continue in 2023, supported by macro and certain industry-specific factors. Days after Me...
IDEAYA Announces Positive Interim Phase 2 Data for Darovasertib and Crizotinib Combination and Successful FDA Type C Meeting on Registrational Trial Design for Accelerated Approval in First-Line Metastatic Uveal Melanoma PR Newswire Confirmed overall response rate (ORR) of 45%...
2023-04-19 09:01:34 ET With several large M&A deals involving biotechs being acquired so far in 2023, RBC Capital Markets says such activity could be on the rise ahead. Given recent M&A activity, we "remind investors that there remains M&A appetite among large pharmas,...
IDEAYA Announces First Patient Dosed in Phase 1 Clinical Trial for IDE161 as Potential First-in-Class PARG Inhibitor Targeting HRD Solid Tumors PR Newswire - Evaluating IDE161 in patients having solid tumors with HRD, with expansion focus in ER+ / Her2- breast cancer with HRD, r...
IDEAYA Biosciences to Participate in Upcoming April 2023 Investor Relations Event PR Newswire SOUTH SAN FRANCISCO, Calif. , April 3, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and...
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) PR Newswire SOUTH SAN FRANCISCO, Calif. , March 31, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery ...
2023-03-24 16:24:16 ET Summary IDEAYA Biosciences, Inc.'s platform is synthetic lethality targeting cancer. The company has produced solid proof of concept data from multiple programs. Cash is strong, and big pharma is interested in IDEAYA Biosciences, Inc. and its work. ...
News, Short Squeeze, Breakout and More Instantly...
IDEAYA Biosciences Inc. Company Name:
IDYA Stock Symbol:
NYSE Market:
IDEAYA Biosciences Inc. Website:
2024-07-10 16:15:02 ET RBC Capital analyst issues OUTPERFORM recommendation for IDYA on July 10, 2024 02:51PM ET. The previous analyst recommendation was Outperform. IDYA was trading at $37.33 at issue of the analyst recommendation. The overall analyst consensus : BUY. ...
2024-07-10 16:00:03 ET Gregory Renza from RBC Capital issued a price target of $61.00 for IDYA on 2024-07-10 14:51:00. The adjusted price target was set to $61.00. At the time of the announcement, IDYA was trading at $37.33. The overall price target consensus is at $35.3...
2024-07-08 17:30:03 ET BTIG analyst issues BUY recommendation for IDYA on July 8, 2024 03:52PM ET. The previous analyst recommendation was Buy. IDYA was trading at $39.51 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst rec...